Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)

Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)

Primary focal segmental glomerulosclerosis (FSGS) is a leading cause of nephrotic syndrome and end-stage renal disease. There are no US Food and Drug Administration−approved therapies for FSGS, and treatment often fails to reduce proteinuria. Endothelin is an important factor in the pathophysiology...

Full description

Bibliographic Details
Main Authors: Radko Komers, Debbie S. Gipson, Peter Nelson, Sharon Adler, Tarak Srivastava, Vimal K. Derebail, Kevin E. Meyers, Pablo Pergola, Meghan E. MacNally, Jennifer L. Hunt, Alvin Shih, Howard Trachtman
Format: Article
Language:English
Published: Elsevier 2017-07-01
Series:Kidney International Reports
Subjects:
endothelin receptor antagonist
focal segmental glomerulosclerosis
irbesartan
nephrotic syndrome
proteinuria
sparsentan
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024917300529

Internet

http://www.sciencedirect.com/science/article/pii/S2468024917300529

Similar Items